DeFi Technologies Announces Shareholder Call to Discuss 2024 Financial Results
TORONTO, March 26, 2025 /PRNewswire/ – (the “Company” or “DeFi Technologies“) (CBOE CA: DEFI) (GR: R9B) (OTC: DEFTF), a financial... Read more.
NetDragon Announces 2024 Annual Financial Results, Fully Embraces the World of Artificial Intelligence
Profit Before Tax Up 19% YoY Final Dividend Increased by 25% YoY to HK$0.5 Per Share HONG KONG, March 26, 2025 /PRNewswire/ — NetDragon Websoft Holdings... Read more.
Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation... Read more.
Mynd Announces Fiscal Year 2024 Results
Highlights Include Sale of a Non-strategic Business Unit, Significant Reduction of Debt, and Implementation of a Share Repurchase Program to Strengthen the Company... Read more.
SOF Support Foundation Accepting Applications for its 2026 Congressional Fellowship Program
SAN DIEGO, March 26, 2025 /PRNewswire/ — SOF (Special Operations Forces) Support Foundation Chair Dominique Plewes announced today that the 2026 application... Read more.
Mission Proven, Space Proven, AI Ready: Aitech to Showcase Next-Gen Rugged Tech Powering AI in Space at the Space Symposium
From AI-Guided Deorbiting to Advanced Pattern of Life Analysis, Aitech to Demo Radiation-Tolerant Solutions Driving the Future of AI for LEO, GEO, Lunar, and Deep... Read more.
Range.com Announces Sponsorship of PGA TOUR Winner Michael Kim
Industry pioneer in AI-powered personal finance partners with leading Professional Golfer MCLEAN, Va., March 26, 2025 /PRNewswire/ — Range, a leading AI-powered... Read more.
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ —... Read more.
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ — Viking... Read more.
Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
New Clinical Data from Phase 2 Trial of LUT014 for the Treatment of Patients With EGFRI-Induced Acneiform Rash Accepted for Oral Presentation at the Clinical Trials... Read more.